Published in J Thorac Cardiovasc Surg on April 03, 2010
Nanoparticles targeting the infarcted heart. Nano Lett (2011) 1.03
Calcium-alginate hydrogel-encapsulated fibroblasts provide sustained release of vascular endothelial growth factor. Tissue Eng Part A (2012) 0.83
Myocardial tissue elastic properties determined by atomic force microscopy after stromal cell-derived factor 1α angiogenic therapy for acute myocardial infarction in a murine model. J Thorac Cardiovasc Surg (2012) 0.82
Dermagraft: Use in the Treatment of Chronic Wounds. Adv Wound Care (New Rochelle) (2012) 0.78
Therapeutic application of nanotechnology in cardiovascular and pulmonary regeneration. Comput Struct Biotechnol J (2013) 0.78
An electrically coupled tissue-engineered cardiomyocyte scaffold improves cardiac function in rats with chronic heart failure. J Heart Lung Transplant (2013) 0.75
Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol (2007) 14.48
The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov (2009) 6.23
Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc (2008) 4.50
Survival and development of neonatal rat cardiomyocytes transplanted into adult myocardium. J Mol Cell Cardiol (2002) 3.79
Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies. J Mol Cell Cardiol (2001) 3.66
Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol (2007) 2.69
Magnitude and time course of microvascular obstruction and tissue injury after acute myocardial infarction. Circulation (1998) 2.30
The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care (2003) 2.09
Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation (2004) 2.06
Correlation of autologous skeletal myoblast survival with changes in left ventricular remodeling in dilated ischemic heart failure. J Thorac Cardiovasc Surg (2005) 2.05
Neovasculogenic therapy to augment perfusion and preserve viability in ischemic cardiomyopathy. Ann Thorac Surg (2006) 1.82
Repair of impaired myocardium by means of implantation of engineered autologous myoblast sheets. J Thorac Cardiovasc Surg (2005) 1.82
Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am J Pathol (2003) 1.52
Washout of transplanted cells from the heart: a potential new hurdle for cell transplantation therapy. Cardiovasc Res (2005) 1.48
Biological gene delivery vehicles: beyond viral vectors. Mol Ther (2009) 1.43
Chronic heart failure induced by coronary artery ligation in Lewis inbred rats. Am J Physiol (1997) 1.31
Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart. Circulation (2004) 1.23
Stromal cell-derived factor and granulocyte-monocyte colony-stimulating factor form a combined neovasculogenic therapy for ischemic cardiomyopathy. J Thorac Cardiovasc Surg (2005) 1.20
Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am Heart J (2001) 1.20
Longer preservation of cardiac performance by sheet-shaped myoblast implantation in dilated cardiomyopathic hamsters. Cardiovasc Res (2006) 1.19
Scaffold-based three-dimensional human fibroblast culture provides a structural matrix that supports angiogenesis in infarcted heart tissue. Circulation (2001) 1.19
Growth factors secreted by fibroblasts: role in healing diabetic foot ulcers. Diabetes Obes Metab (1999) 1.16
Cardiac patch constructed from human fibroblasts attenuates reduction in cardiac function after acute infarct. Tissue Eng (2006) 1.10
Locally overexpressing hepatocyte growth factor prevents post-ischemic heart failure by inhibition of apoptosis via calcineurin-mediated pathway and angiogenesis. Arch Med Res (2008) 1.10
Echocardiographic assessment of cardiac structure and function in rats. Heart Lung Circ (2002) 1.05
Implantation of a three-dimensional fibroblast matrix improves left ventricular function and blood flow after acute myocardial infarction. Cell Transplant (2009) 1.05
Induction of angiogenesis and inhibition of apoptosis by hepatocyte growth factor effectively treats postischemic heart failure. J Card Surg (2005) 1.04
Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg (1999) 1.02
Pro-angiogenic cytokines as cardiovascular therapeutics: assessing the potential. BioDrugs (2008) 0.97
Autologous skeletal myoblast transplantation in patients with nonacute myocardial infarction: 1-year follow-up. J Thorac Cardiovasc Surg (2006) 0.90
Improvement of contractility accompanies angiogenesis rather than arteriogenesis in chronic myocardial ischemia. Vascul Pharmacol (2006) 0.86
Robotic minimally invasive cell transplantation for heart failure. J Thorac Cardiovasc Surg (2006) 0.85
Induction of collateral artery growth and improvement of post-infarct heart function by hepatocyte growth factor gene transfer. Acta Pharmacol Sin (2006) 0.85
Therapeutic Angiogenesis Using Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor Using Various Delivery Strategies. Curr Interv Cardiol Rep (1999) 0.83
Chronic infarct-related artery occlusion is associated with a reduction in capillary density. Effects on infarct healing. Eur J Heart Fail (2005) 0.80
Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation (2011) 14.00
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 7.94
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2012) 6.94
Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N Engl J Med (2013) 6.21
Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance. Am J Physiol Heart Circ Physiol (2006) 3.78
Saddle-shape annuloplasty increases mitral leaflet coaptation after repair for flail posterior leaflet. Ann Thorac Surg (2011) 2.42
Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical circulatory support. J Heart Lung Transplant (2008) 2.32
Neonatal lethality in transgenic mice expressing prion protein with a deletion of residues 105-125. EMBO J (2007) 2.12
The cellular prion protein (PrP(C)): its physiological function and role in disease. Biochim Biophys Acta (2007) 2.09
Antegrade thoracic stent grafting during repair of acute DeBakey I dissection prevents development of thoracoabdominal aortic aneurysms. Ann Thorac Surg (2009) 1.95
Neovasculogenic therapy to augment perfusion and preserve viability in ischemic cardiomyopathy. Ann Thorac Surg (2006) 1.82
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 1.80
Mutant PrP is delayed in its exit from the endoplasmic reticulum, but neither wild-type nor mutant PrP undergoes retrotranslocation prior to proteasomal degradation. J Biol Chem (2003) 1.64
Significance of malperfusion syndromes prior to contemporary surgical repair for acute type A dissection: outcomes and need for additional revascularizations. Eur J Cardiothorac Surg (2007) 1.59
Emergency extracorporeal life support for asphyxic status asthmaticus. Respir Care (2007) 1.59
Nitrogen balance and delta15N: why you're not what you eat during nutritional stress. Rapid Commun Mass Spectrom (2005) 1.55
Mutant prion protein expression is associated with an alteration of the Rab GDP dissociation inhibitor alpha (GDI)/Rab11 pathway. Mol Cell Proteomics (2009) 1.52
Advances in the treatment of acute type A dissection: an integrated approach. Ann Thorac Surg (2002) 1.52
Transmyocardial revascularization to enhance myocardial vasculogenesis and hemodynamic function. J Thorac Cardiovasc Surg (2008) 1.49
Ascending aortic cannulation in acute type a dissection repair. Ann Thorac Surg (2013) 1.49
Who needs an RVAD in addition to an LVAD? Cardiol Clin (2011) 1.46
HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.46
Early planned institution of biventricular mechanical circulatory support results in improved outcomes compared with delayed conversion of a left ventricular assist device to a biventricular assist device. J Thorac Cardiovasc Surg (2009) 1.44
Local excision for early stage rectal cancer in patients over age 65 years: 2000-2009. Dis Colon Rectum (2015) 1.40
Biochemical dysfunction in heart mitochondria exposed to ischaemia and reperfusion. Biochem J (2005) 1.40
Cytosolic prion protein (PrP) is not toxic in N2a cells and primary neurons expressing pathogenic PrP mutations. J Biol Chem (2005) 1.39
Left main coronary embolism. J Invasive Cardiol (2006) 1.39
Molecular distinction between pathogenic and infectious properties of the prion protein. J Virol (2003) 1.38
Apelin has in vivo inotropic effects on normal and failing hearts. Circulation (2004) 1.37
Prion protein repeat expansion results in increased aggregation and reveals phenotypic variability. Mol Cell Biol (2007) 1.31
Nitrogen balance and delta15N: why you're not what you eat during pregnancy. Rapid Commun Mass Spectrom (2004) 1.29
Stromal cell-derived factor-1alpha activation of tissue-engineered endothelial progenitor cell matrix enhances ventricular function after myocardial infarction by inducing neovasculogenesis. Circulation (2010) 1.28
Postoperative mortality after esophagectomy for cancer: development of a preoperative risk prediction model. Ann Surg Oncol (2008) 1.27
Fate of the residual distal and proximal aorta after acute type a dissection repair using a contemporary surgical reconstruction algorithm. Ann Thorac Surg (2007) 1.26
Prion protein at the crossroads of physiology and disease. Trends Neurosci (2011) 1.26
Computational protein design to reengineer stromal cell-derived factor-1α generates an effective and translatable angiogenic polypeptide analog. Circulation (2011) 1.20
Outcomes of the RESTOR-MV Trial (Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve). J Am Coll Cardiol (2010) 1.20
Bax deletion prevents neuronal loss but not neurological symptoms in a transgenic model of inherited prion disease. Proc Natl Acad Sci U S A (2004) 1.18
An N-terminal fragment of the prion protein binds to amyloid-β oligomers and inhibits their neurotoxicity in vivo. J Biol Chem (2013) 1.18
Robot-assisted pharyngeal and laryngeal microsurgery: results of robotic cadaver dissections. Laryngoscope (2005) 1.17
Dimerization of F0F1ATP synthase from bovine heart is independent from the binding of the inhibitor protein IF1. Biochim Biophys Acta (2002) 1.14
Biochemical analysis of MST1 kinase: elucidation of a C-terminal regulatory region. Biochemistry (2008) 1.14
Minimally invasive approach provides at least equivalent results for surgical correction of mitral regurgitation: a propensity-matched comparison. J Thorac Cardiovasc Surg (2013) 1.13
Neurotoxic mutants of the prion protein induce spontaneous ionic currents in cultured cells. J Biol Chem (2010) 1.12
A novel, drug-based, cellular assay for the activity of neurotoxic mutants of the prion protein. J Biol Chem (2009) 1.11
Outcomes using extracorporeal life support for adult respiratory failure due to status asthmaticus. ASAIO J (2009) 1.10
Mutational analysis of topological determinants in prion protein (PrP) and measurement of transmembrane and cytosolic PrP during prion infection. J Biol Chem (2003) 1.10
Acute cellular uptake of abnormal prion protein is cell type and scrapie-strain independent. Virology (2008) 1.10
Predicting right ventricular failure in the modern, continuous flow left ventricular assist device era. Ann Thorac Surg (2013) 1.09
Viral gene transfer of the antiapoptotic factor Bcl-2 protects against chronic postischemic heart failure. Circulation (2002) 1.08
Design, rationale, and initiation of the Surgical Interventions for Moderate Ischemic Mitral Regurgitation Trial: a report from the Cardiothoracic Surgical Trials Network. J Thorac Cardiovasc Surg (2011) 1.08
Circulating fibrocytes correlate with bronchiolitis obliterans syndrome development after lung transplantation: a novel clinical biomarker. Ann Thorac Surg (2011) 1.07
Neurodegenerative illness in transgenic mice expressing a transmembrane form of the prion protein. J Neurosci (2005) 1.07
Adenosine A₂A agonist improves lung function during ex vivo lung perfusion. Ann Thorac Surg (2011) 1.07
A naturally occurring C-terminal fragment of the prion protein (PrP) delays disease and acts as a dominant-negative inhibitor of PrPSc formation. J Biol Chem (2011) 1.07
Aggregated, wild-type prion protein causes neurological dysfunction and synaptic abnormalities. J Neurosci (2008) 1.07
Three-dimensional echocardiographic analysis of mitral annular dynamics: implication for annuloplasty selection. Circulation (2012) 1.06
Surgical revision after percutaneous mitral repair with the MitraClip device. Ann Thorac Surg (2010) 1.05
Blocking the development of postischemic cardiomyopathy with viral gene transfer of the apoptosis repressor with caspase recruitment domain. J Thorac Cardiovasc Surg (2003) 1.05
Robotic microlaryngeal surgery: a technical feasibility study using the daVinci surgical robot and an airway mannequin. Laryngoscope (2005) 1.05
Retrograde and antegrade cerebral perfusion: results in short elective arch reconstructive times. Ann Thorac Surg (2010) 1.04
Non-infectious aggregates of the prion protein react with several PrPSc-directed antibodies. J Neurochem (2008) 1.04
Induction of angiogenesis and inhibition of apoptosis by hepatocyte growth factor effectively treats postischemic heart failure. J Card Surg (2005) 1.04
An N-terminal polybasic domain and cell surface localization are required for mutant prion protein toxicity. J Biol Chem (2011) 1.03
Prion neurotoxicity: insights from prion protein mutants. Curr Issues Mol Biol (2009) 1.02
Paratracheal air cysts using low-dose screening chest computed tomography: clinical significance and imaging findings. Jpn J Radiol (2011) 1.02
Postoperative right ventricular failure after left ventricular assist device placement is predicted by preoperative echocardiographic structural, hemodynamic, and functional parameters. J Card Fail (2013) 1.02
GFP-tagged prion protein is correctly localized and functionally active in the brains of transgenic mice. Neurobiol Dis (2004) 1.02
Human prion proteins with pathogenic mutations share common conformational changes resulting in enhanced binding to glycosaminoglycans. Proc Natl Acad Sci U S A (2007) 1.02
Optimal promoter usage for lentiviral vector-mediated transduction of cultured central nervous system cells. J Neurosci Methods (2010) 1.01
Acute myocardial rescue with endogenous endothelial progenitor cell therapy. Heart Lung Circ (2010) 1.01
Visualization of prion infection in transgenic mice expressing green fluorescent protein-tagged prion protein. J Neurosci (2005) 0.99
Prion protein with an octapeptide insertion has impaired neuroprotective activity in transgenic mice. EMBO J (2007) 0.98
A nine amino acid domain is essential for mutant prion protein toxicity. J Neurosci (2011) 0.98
N-terminally deleted forms of the prion protein activate both Bax-dependent and Bax-independent neurotoxic pathways. J Neurosci (2007) 0.98
Placental growth factor provides a novel local angiogenic therapy for ischemic cardiomyopathy. J Card Surg (2006) 0.98
Fishing for prion protein function. PLoS Biol (2009) 0.97
Ventricular assist device implant in the elderly is associated with increased, but respectable risk: a multi-institutional study. Ann Thorac Surg (2013) 0.97
Mammalian prion protein suppresses Bax-induced cell death in yeast. J Biol Chem (2005) 0.97
Pro-angiogenic cytokines as cardiovascular therapeutics: assessing the potential. BioDrugs (2008) 0.97
A deleted prion protein that is neurotoxic in vivo is localized normally in cultured cells. J Neurochem (2008) 0.97
Transventricular mitral valve operations. Ann Thorac Surg (2011) 0.96
Copper and zinc cause delivery of the prion protein from the plasma membrane to a subset of early endosomes and the Golgi. J Neurochem (2003) 0.96